
usd pm et
summari primarili manufactur product orthoped
price-to-earnings oper ep
past perform indic futur perform reli upon
analysi prepar equiti analyst
feb pm stock trade
star recommend
recent chang hold
sell target price
recent chang
highlight section stock report
invest rationale/risk section
stock report updat shortli
latest news stori marketscop
hold sell lower
target price reflect
anticip advers impact
compani valu updat price
reflect forward price-to-earnings ratio
ep estim
lower ep estim
time rais opinion
share think recent
substanti declin share valu
februari reduc amount
downsid risk share /kevin huang cfa
risk assess reflect zimmer oper
highli competit industri character rel
short product life cycl requir signific number
new product maintain market share mani custom
reimburs medicar restrict
budgetari environ could result price pressur
howev think market leadership posit
divers product offer allevi inher
may ep estim base cfra oper earn
histor earn report compani report
cash dividend paid last year
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
corpor overview zimmer biomet global leader musculoskelet healthcar form
june merger zimmer hold biomet primarili design develop
manufactur market orthopaed reconstruct product sport medicin biolog extrem
trauma product offic base technolog spine craniomaxillofaci cmf thorac product
dental implant relat surgic product market sell product three princip
channel direct health care institut hospit stock distributor
health care dealer directli dental practic dental laboratori break offer
product categori knee revenu hip dental spine
cmf
reconstruct implant use restor function lost due diseas trauma joint
knee hip shoulder elbow knee product total knee replac surgeri joint
replac partial knee reconstruct earli intervent joint preserv hip offer
product total hip replac hip implant procedur involv use bone cement attach
affix prosthet compon surround bone product categori
includ surgic sport medicin biolog foot ankl extrem trauma product
zbh spine product busi manufactur devic surgic instrument deliv comprehens
solut individu back neck pain caus degen condit deform
traumat injuri spine cmf divis includ face skull reconstruct product addit
product fixat stabil bone chest dental product primarili compris dental
reconstruct implant dental prosthet product dental regen product
competit landscap orthopaed broader musculoskelet care industri highli
competit global market zbh knee hip product major competitor includ
depuy synth compani johnson johnson stryker corpor smith nephew plc
spine cmf categori compet global primarili spinal biolog busi
plc depuy synth compani stryker corpor inc globu medic inc
dental implant categori compet primarili nobel biocar hold ag part
corpor straumann hold ag
competit within industri primarili base price technolog innov qualiti reput
custom servic key factor zbh continu success futur abil develop
new product improv exist product technolog
impact major develop receiv mani post-inspect highlight
violat rule regul observ inspect food drug
administr fda detail observ need need correct zbh warsaw
indiana-bas manufactur plant earli continu remedi manufactur issu
origin expect warsaw plant issu resolv end howev zbh
manag expect februari readi fda reinspect end although
orthoped surgeri tend sticki custom extend period zbh manufactur
under-capac may led signific market share loss manufactur remedi process
also result inventori constraint caus cut guidanc multipl time
june zimmer acquir biomet billion connect transact zimmer
chang name zimmer biomet ticker symbol new york stock exchang
zmh combin compani leader musculoskelet market juli zimmer acquir
ldr hold billion ldr medic devic compani focus proprietari surgic
technolog treatment patient suffer spinal disord
financi trend revenu dec increas billion billion
adjust ep declin year-over-year prior year reflect five-year
compound annual growth rate compound-annual-growth-rate growth pressur zbh remedi
effort manufactur plant warsaw indiana zbh free cash flow defin cash flow
oper less capit expenditur expand billion billion prior-year
period septemb zbh net debt total capit leverag ratio net debt
ebitda
senior vice presid
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
slightli under-valued usd
neutral sinc februari technic indic
neutral
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million usd
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
fundament outlook health care
next month neutral expect
compani continu achiev robust organ
growth mid- high-single-digit revenu
growth driven new product
data provid estim world-wide medic
devic sale grow
time think potenti slowdown
macroeconom growth could pressur
industri driver yet sub-industri
includ mani product area
histor recession-resist
equip use non-elect procedur
gener see posit long-term
fundament medic devic manufactur
includ increas global demand
popul rise outlay
result steadi flow innov product
revenu growth
polit regulatori perspect
medic devic industri larg avoid
scrutini unlik area health
drug maker fact medic devic tax
final repeal decemb remov
signific risk sale devic maker
think industri continu
dwindl industri come back
favor especi sinc valuat health
rel
forward price-to-earn basi think
higher valuat sub-industri
mostli warrant margin expans
revenu growth opportun associ
 medic devic regul
mdr go effect may
follow vitro devic
regul ivdr goe effect
devic compani made much
commentari around introduct mdr
reason believ new
regul could neg impact
industri exampl juli
submit letter world trade
organ request mdr ivdr
delay three year also novemb
associ critic slow piecem
implement new regulatori
accord evalu
billion valu prior
five-year averag deal total
billion industri debt level measur
net debt rel total capit appear
declin substanti follow
sever year increas think
industri could see increas deal
especi new ceo sever
major firm
expect industri earn rise
low-double-digit percentag driven sale
new product command higher
margin project industri oper
ebit margin
estim margin
 health equip
valu composit index
 health equip
sub-index rose vs declin
base index
five-year market price perform
note sector sub-industri inform base
past perform indic futur perform
reli upon
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
analyst research note compani news
pm et cfra rais opinion share hold
sell lower target price
reflect anticip advers impact compani valu
updat price reflect forward price-to-earnings ratio ep
estim lower ep estim
time rais opinion share think recent
substanti declin share valu approxim declin sinc late
februari reduc amount downsid risk share /kevin huang
slow market share loss optimist see long-term potenti
recent launch rosa knee system total knee arthroplasti tka
think factor limit near-term success rosa sale
exampl rosa key competit mako system fda approv
tka almost four year rosa earli move enabl establish
robust data set mako tka creat reput leader
robot-assist knee replac declin econom condit consum
sentiment may also prove unfavor environ launch sale
pm et cfra maintain hold opinion share zimmer biomet
hold inc rais target
ep estim -- peer-averag due
continu remedi effort need address fda concern ep
vs consensu maintain ep
estim respect sale increas yoy
constant currenc basi volume/mix improv contribut
growth price neg impact constant currenc
basi revenu yoy america
emea asia pacif respect continu focu short-term
prioriti set achiev long-term in-line-with-market growth
prioriti includ address suppli chain issu optim talent
structur ensur success recent upcom product launch
rosa robot platform earli stage limit launch
pm et cfra reiter sell opinion share zimmer biomet
hold inc lift target
reflect forward price-to-earnings multipl ep estim
ep vs estim keep
ep estim commenc ep sale
increas yoy constant currenc cc billion
expect due strong knee sale particularli asia pacif
announc today begun multi-year restructur plan reduc
cost drive mix shift toward high growth product robot
informat zbh restructur initi expect cost
million half charg recogn
compani aim gener annual oper expens save
million enabl oper margin least
although shown posit momentum recent quarter
yet fulli convinc durabl zbh turnaround /kevin huang
pm et cfra maintain sell opinion share zimmer biomet
hold inc lift target price
reflect forward price-to-earnings multipl ep estim
ep vs estim increas
ep estim keep ep
sale increas yoy constant currenc cc
billion revenu growth acceler across board cc basi revenu
america grew emea asia pacif
main focu analyst earn call perform
recent launch rosa knee offer manag note rosa contribut
less half overal revenu growth global knee demand
high manag also emphas would take time rosa drive
higher earn revenu growth face stronger price pressur
peer price neg impact sale vs
pm et cfra reiter sell opinion share zimmer biomet
hold inc lift target price
reflect forward price-to-earnings multipl ep estim
rais price-to-earnings multipl reflect sooner-than-expect growth
ep vs exceed estim increas
ep ep sale
increas yoy constant currenc basi billion
expect due constant currenc cc growth knee vs
manag expect compani achiev cc revenu growth in-lin
market six month ahead prior expect
quarter perform encourag think still earli
determin well rosa compet whether revers market share
loss next year continu face stronger price pressur
peer price neg impact sale vs
et cfra lower opinion share sell
hold lower price target
reflect forward price-to-earnings multipl ep estim
reduc ep ep
believ consensu expect regard abil
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd fiscal year analyst estim
earn per share grow usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
redistribut reproduct prohibit without prior written permiss copyright cfra
content includ rate credit-rel analys data valuat model softwar
applic output therefrom part thereof content may modifi
revers engin reproduc distribut form mean store
databas retriev system without prior written permiss cfra content shall
use unlaw unauthor purpos cfra third-parti provid
well director offic sharehold employe agent guarante
accuraci complet timeli avail content
past perform necessarili indic futur result
document may contain forward-look statement forecast forecast
reliabl indic futur perform
report intend constitut offer solicit buy sell
secur engag invest activ report inform purpos
recommend report made respect particular investor
type investor secur financi instrument strategi mention herein may
suitabl investor materi intend specif investor
take account investor particular invest object financi situat
need act recommend materi consid whether
suitabl particular circumst necessari seek profession advic
cfra may licens certain intellectu properti provid servic otherwis
busi relationship certain issuer secur subject cfra
research report includ exchange-trad invest whose invest object
substanti replic return proprietari index cfra case cfra
paid fee tie amount asset invest fund volum trade
activ fund invest fund may result cfra receiv compens
addit subscript fee compens servic render cfra
howev part cfra compens servic tie recommend
rate addit inform subject compani may avail upon request
cfra financi data provid global market intellig document contain
global industri classif standard gic develop and/or exclus
properti inc global market intellig gic servic mark
 global market intellig licens use cfra
disclaim notic
certain inform report provid global inc and/or affili
subsidiari collect global inform subject follow
disclaim notic copyright global market intellig affili
applic right reserv noth contain herein invest advic
refer particular invest secur credit rate observ
concern secur invest provid recommend buy
sell hold invest secur make invest decis may
contain inform obtain third parti includ rate credit rate
agenc reproduct distribut inform third parti content
form prohibit except prior written permiss global
relat third parti applic neither third parti provid guarante
accuraci complet timeli avail inform includ rate
respons error omiss neglig otherwis regardless
caus result obtain use inform content
includ rate credit rate statement opinion statement
fact recommend purchas hold sell secur address
suitabl secur suitabl secur invest purpos
reli invest advic
